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There is general agreement that clinical disease activity indexes in inflammatory bowel disease require improvement. The clinical 
disease activity indexes were composite scores designed to be used as 
efficacy measures in randomized controlled clinical trials; however, 
some of them are also used sporadically in clinical practice. More 
recently, the clinical disease activity indexes have been regularly sup-
ported by more objective measures of inflammatory activity such as 
endoscopic scores, and/or C-reactive protein, fecal calprotectin levels, 
etc. In addition, patient-reported disease specific or generic quality of 
life scores have been regularly used to support clinical efficacy of a 
candidate drug in trials, although these are not widely used in clinical 
practice. All of these have been the cornerstone of drug development 
in inflammatory bowel disease, despite their imperfections (1).
The composite clinical disease activity indexes include patient-
reported items, physician-reported items, laboratory measures and, in 
some cases, endoscopy scores in various permutations and combina-
tions, and the different items may be unweighted or weighted. These 
activity indexes generally contain several subjective items prone to 
imprecision, and may drive up placebo response scores unpredictably, 
depending on the time point of assessment. In addition, the physician-
reported items may be subject to interpretation and prone to distortion 
in clinical trial settings. Endoscopy scores are also physician reported 
and, hence, there is an increasing trend toward centralized readouts to 
have more consistent scoring of endoscopic appearance. In pediatric 
inflammatory bowel disease, the clinical disease activity indexes are 
often modified for this specific age group. 
In the current issue of the Journal, El-Matary (2) (pages 536-542) 
has provided an excellent review of the evolution of patient-reported 
outcome measures in inflammatory bowel disease and the various regu-
latory agency recommendations driving changes in the way we meas-
ure the efficacy of drugs in clinical trials. In addition, there is an 
increasing desire among physicians caring for inflammatory bowel 
disease patients to incorporate scoring systems in their clinical practice 
to introduce more objectivity in their assessment of patients. Electronic 
medical records are incorporating such scoring systems in their phys-
ician input interface. Various electronic platforms are being designed 
for real-time capture of patient-reported outcome measures. These are 
encouraging developments in improving the overall standard of care in 
inflammatory bowel disease. 
However, there are significant challenges and hurdles to be over-
come to introduce patient-reported outcome measures widely in 
inflammatory bowel disease and eliminate physician-reported out-
comes. The heterogeneity of inflammatory bowel disease presenta-
tions is remarkable, and symptoms may arise from a multitude of 
contributing and confounding factors. These factors are highlighted 
in Box 1, although the list is by no means exhaustive. These may vary 
at different phases of disease and may be coloured by previous experi-
ence, quality of communication with the physician and members of 
the multidisciplinary team, as well as other factors such as occupation 
and education level of the patient, family support and belief systems. 
While some of these may be controlled by inclusion and exclusion 
criteria in clinical trials, as well as by the randomization process, there 
is little doubt that not all factors can be controlled. Combining 
patient-reported outcome measures with objective measures, such as 
endoscopic appearance (itself a physician-reported item, even in cen-
tral reporting systems), may be more robust, although we still need 
more information regarding the exact operating characteristics in 
large multicentre clinical trials. In clinical practice, the heterogeneity 
can be enormous and well-trained physician input is essential. 
Therefore, we must find a balance among patient-reported outcomes, 
physician assessment, laboratory parameters and other objective 
measures, such as cross-sectional imaging and endoscopy (with inher-
ent interobserver agreement issues), to make the correct decisions. 
Although significantly more work must be done, replacing the phys-
ician is not an option. 
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bOX 1
Contributors to patient-reported outcome measures 
in inflammatory bowel disease that are not directly 
related to inflammatory activity
● Irritable bowel syndrome/visceral hypersensitivity
● Complications such as strictures or fistulae or neoplasm
● Loss of function (eg, colon) due to chronic inflammation
● Concomitant infections
● Psychosocial issues, including anxiety and depression
● Iatrogenic factors, medical or surgical
● Bile acid malabsorption
● Small bowel bacterial overgrowth
● Extraintestinal manifestations not related to inflammatory 
activity
● Alternative medical care
● Health care and family/friends support system of the patient
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